Home About Us 2003 Innovators Past Innovators Facts About Substance Abuse Press/Events FAQs Contacts Us

Tobacco Companies Designed Cigarettes "To Addict Women,"

Analysis of Industry Documents Reveals How Mistaken Health Beliefs and Behavioral Differences Were Exploited in Order to Enlarge Female Cigarette Market

An analysis of tobacco industry documents provides evidence that cigarette companies intentionally modified their products to promote female smoking by emphasizing attributes they knew would appeal to women – stylishness and taste, as well as perceived health benefits. According to the authors, the study presents particularly troubling implications for world health, as tobacco companies seek to increase smoking among women in developing countries.  The documents, made public following the 1998 Tobacco Master Settlement Agreement, are examined in a paper in the June 2005 issue of ADDICTION, an international scientific journal.   Click here to view the full reportAddiction 2005;100:837-851.

Previous studies demonstrated that marketing strategies have contributed to the association of smoking with appealing attributes including female liberation, glamour, success and thinness.  Until now, however, the role of product design in targeting cigarettes to address how and why women smoke was less well understood. 

“These internal documents reveal that the tobacco industry’s targeting of women goes far beyond marketing and advertising,” says lead author Carrie Murray Carpenter, M.S., Research Analyst, Tobacco Control Research and Training Program, Harvard School of Public Health.  Carpenter and colleagues reveal that, for more than 20 years, the industry undertook a major effort to identify gender-based differences in motivational factors, smoking patterns, and product preferences in order to promote smoking among women and girls. 

The Carpenter team say the resulting products exploited mistaken health notions about the relative safety of light cigarettes; created false perceptions of social and health effects through reduced sidestream smoke, appearance and odor and improved aroma and aftertaste; matched female taste preferences through flavored, smooth and mild-tasting cigarettes; and targeted physiological and inhalation differences between women and men with greater ease of draw, increased sensory pleasure and altered tar and nicotine levels.  The documents also show that cigarette makers went so far as to explore the use of appetite suppressants in cigarettes to promote smoking-mediated weight control, according to the researchers.

“Carpenter and her group reveal that cigarette designs and ingredients were manipulated to make the cigarettes more palatable to women and to complement advertising allusions of smooth, healthy, weight-controlling, stress-reducing smoke,” according to an accompanying editorial in ADDICTION by Jack E. Henningfield, Ph.D. and colleagues at The Johns Hopkins University School of Medicine and Johns Hopkins Bloomberg School of Public Health.  “For example, so called ‘light’ and ‘reduced tar’ cigarettes were designed to undermine prevention and cessation efforts by addressing smokers’ concerns about the health effects of smoking – but not by reducing the adverse health effects.”  Henningfield, who serves as director of The Robert Wood Johnson Foundation’s Innovators Combating Substance Abuse program at Johns Hopkins University, is Adjunct Professor of Behavioral Biology, Department of Psychiatry and Behavioral Sciences in the university’s School of Medicine.  To view Editorial, click here:  Addiction 2005;100:735-736.

Quotes from tobacco industry documents are sprinkled throughout the paper.  One, from a 1993 internal Philip Morris report, describes a rationale for designing longer, slimmer cigarettes and creating the illusion of a “healthier” product:

“Most smokers have little notion of their brand’s tar and nicotine levels.  Perception is more important than reality, and in this case the perception is of reduced tobacco consumption.”

The documents reveal that, beginning in the 1970s, the companies undertook internal research to identify numerous psychological and behavioral factors contributing to female-specific needs and motivations to smoke.  As brand preferences shifted between the 1970s and 1990s the tobacco companies modified their product designs accordingly.  “While the tobacco industry continues to target female smokers today, their current strategies are more multi-faceted and less readily identifiable than they were decades ago,” the authors note.

The new paper’s analysis suggests that the tobacco industry’s behavior has particularly troubling implications for health officials in the developing world.  While male smoking rates are declining throughout the world, female smoking rates are expected to continue increasing and reach 20 percent by 2025, driven by the growth of female markets in developing countries. Published research predicts the rapid growth of tobacco-related disease among women in these countries, and establishes that industry efforts to target women have resulted in the elevated female smoking and related disease rates that we see today.

Henningfield views these revelations as a “call to action” for the tobacco control community:  “Now that we know tobacco companies designed cigarettes to addict women, we need to look at prevention and cessation strategies to counter these efforts.  Our most pressing priority should be to examine how Carpenter’s findings can be used to counter the rising tide of smoking in women in developing countries, so that we don’t see the corresponding increase in smoking-related deaths that we’ve already seen in the developed world.”

Innovators Combating Substance Abuse is a national program of The Robert Wood Johnson Foundation that recognizes and rewards those who have made substantial, innovative contributions of national significance in the field of substance abuse. Each award includes a grant of $300,000, which is used to conduct a project over a period of up to three years that advances the field.  The program addresses problems related to alcohol, tobacco and illicit drugs, through education, advocacy, treatment and policy research and reform at the national, state and local levels.  The Innovators program is run by a national program office at The Johns Hopkins University School of Medicine.  For more information on Innovators Combating Substance Abuse, please visit www.innovatorsawards.org.

Johns Hopkins is one of the world's premier centers for scholarship, research and patient care. The university and The Johns Hopkins Health System are separate, but closely allied, institutions. Founded in Baltimore, they now reach across the Baltimore-Washington area, with additional facilities in China, Italy and Singapore and partnerships around the world. The university comprises eight schools, a research and development division called the Applied Physics Laboratory and a number of institutes and centers.

The Health System, which has its origins in the founding of the world-famous Johns Hopkins Hospital, now comprises three hospitals, as well as other elements of an integrated system, from a community physicians group to home care.  Johns Hopkins Medicine, established in 1995 to unite Hopkins' biomedical research, clinical, teaching and business enterprises, brings together The Johns Hopkins University of School of Medicine and its faculty with the facilities and programs of The Johns Hopkins Health System.  The $2.7 billion enterprise is one of the largest employers in Maryland.  Its components consistently are named at the top of national rankings for best hospital and best school of medicine, and its faculty consistently win the largest share of NIH research funds.  Results of this research continue to advance efforts to diagnose, treat and prevent many diseases.

Harvard School of Public Health is dedicated to advancing the public's health through learning, discovery, and communication. More than 300 faculty members are engaged in teaching and training the 900-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children's health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit: www.hsph.harvard.edu

Dennis Tartaglia,(212) 481-7000, Dennist@mbooth.com (for Henningfield, et. al.)
Trent Stockton,  (410) 955-8665, Tstockt1@jhmi.edu, (for Henningfield, et. al.)  
Robin Herman,   (617) 432-4752, Rherman@hsph.harvard.edu, (for Carpenter, et. al.)

Copyright 2004 The Johns Hopkins University. Baltimore, Maryland.
All rights reserved. Last Updated November 7, 2008

About Us  |  The Innovators  |  Other Resources  |  Facts About Substance Abuse  |  Press/Events
Contact Us  |  FAQs  |  Home